Veligrotug for Thyroid Eye Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but subsequently had a disease recurrence.
Are You a Good Fit for This Trial?
This trial is for people with moderate to severe thyroid eye disease (TED) who previously improved after teprotumumab treatment but then had their symptoms return. Participants must have a confirmed diagnosis and meet certain health requirements.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- veligrotug (LUMVOA™)
Trial Overview
The study is testing the safety and effectiveness of veligrotug (LUMVOA™), a new medication, in treating TED that has come back after initial improvement with teprotumumab. All participants will receive veligrotug.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive veligrotug10 mg/kg as an intravenous (IV) infusion every 3 weeks (Q3W) for 12 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viridian Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.